Data Sharing Statement


Data
Data available: Yes
Data types: Deidentified participant data, Other (please specify)
Additional Information: Redacted protocols and clinical study reports from clinical trials in patients.
When available: With publication

Supporting Documents
Document types: None

Additional Information
Who can access the data: Data will be shared with qualified scientific and medical researchers, upon researcher's request.
Types of analyses: Data will be shared as necessary for conducting legitimate research.
Mechanisms of data availability: Data will be made available upon researcher's request; such requests must be submitted in writing to the company's data sharing portal. More information can be found at https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html.
Any additional restrictions: For all new products or new indications approved in both the European Union and the United States after January 1, 2014, Merck KGaA, Darmstadt, Germany will share patient-level and study-level data after deidentification, as well as redacted study protocols and clinical study reports from clinical trials in patients. These data will be shared with qualified scientific and medical researchers, upon researcher's request, as necessary for conducting legitimate research. Such requests must be submitted in writing to the company's data sharing portal. More information can be found at https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html. Where Merck KGaA has a co-research, co-
development or co-marketing/co-promotion agreement or where the product has been out-licensed, it is recognized that the responsibility for disclosure may be dependent on the agreement between parties. Under these circumstances, Merck KGaA will endeavour to gain agreement to share data in response to requests.